KR930009605A - 소염 또는 진통제 - Google Patents

소염 또는 진통제 Download PDF

Info

Publication number
KR930009605A
KR930009605A KR1019920023309A KR920023309A KR930009605A KR 930009605 A KR930009605 A KR 930009605A KR 1019920023309 A KR1019920023309 A KR 1019920023309A KR 920023309 A KR920023309 A KR 920023309A KR 930009605 A KR930009605 A KR 930009605A
Authority
KR
South Korea
Prior art keywords
nonsteroidal anti
inflammatory agent
pharmaceutical composition
inflammatory
iii
Prior art date
Application number
KR1019920023309A
Other languages
English (en)
Inventor
스테이블스 로저
Original Assignee
알란 헤스케스
글락소 그룹 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919126027A external-priority patent/GB9126027D0/en
Priority claimed from GB929206083A external-priority patent/GB9206083D0/en
Application filed by 알란 헤스케스, 글락소 그룹 리미티드 filed Critical 알란 헤스케스
Publication of KR930009605A publication Critical patent/KR930009605A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

본 발명은 염증 질환의 치료 또는 예방 및 진통에 있어서 (ⅰ) 라니티딘 비스무트 시트레이트 및 (ⅱ) 비스테로이드성 소염제의 용도에 관한 것이다. 본 발명은 상기 (ⅰ) 및 (ⅱ)의 화합물 모두를 함유하는 제약 조성물을 제공한다.

Description

소염 또는 진통제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 염증 질환의 치료 또는 예방, 또는 진통을 위한 동시, 별개 또는 순차적 투여용 복합 제제로서 (ⅰ) 라니티딘 비스무트 시트레이트 및 (ⅱ) 비스테로이드성 소염제를 함유하는 약제.
  2. (ⅰ) 라니티딘 비스무트 시트레이트 및 임의로 (ⅱ) 비스테로이드성 소염제, 및 제약상 허용되는 담체 또는 부형제로 이루어진 인간 또는 동물에 있어서 비스테로이드성 소염제에 의한 위장 손상의 예방 또는 치료용 제약 조성물.
  3. 제2항에 있어서, 비스테로이드성 소염제가 아스피린, 인도메타신, 이부프로펜, 피록시캄, 페노프로펜, 디클로페낙, 펜부펜, 페프라존, 펜클로페낙, 플루페남산, 플루비프로펜, 옥시펜부타존, 페닐부타존, 술린닥 및 톨메틴으로부터 선택되는 제약 조성물.
  4. 제2항에 있어서, 화합물(ⅰ)이 정제로서 제조되는 제약 조성물.
  5. 제4항에 있어서, 화합물(ⅰ)이 단위 투여당 200-800㎎의 투여량으로 투여되는 제약 조성물.
  6. (ⅰ) 라니티딘 비스무트 시트레이트 및 (ⅱ) 비스테로이드성 소염제, 및 제약상 허용되는 담체 또는 부형제로 이루어지는, 인간 또는 동물에 있어서 염증 질환의 예방 또는 치료, 또는 진통을 위한 경구용 제약 조성물.
  7. 제6항에 있어서, 비스테로이드성 소염제가 아스피린, 인도메타신, 이부프로펜, 피록시캄, 페노프로펜, 케토프로펜, 나프록센, 메페남산, 디플루니살, 베노릴레이트, 아조프로파존, 디클로페낙, 펜부펜, 페프라존, 펜클로페낙, 플루페남산, 플루비프로펜, 옥시펜부타존, 페닐부타존, 슬린닥 및 톨메틴으로부터 선택되는 제약 조성물.
  8. 한 용기에는 (ⅰ) 라니티딘 비스무트 시트레이트를 함유하고, 다른 용기에는 (ⅱ) 비스테로이드성 소염제를 함유하는, 염증 질환의 예방 또는 치료, 또는 진통용 이중 용기 팩(twin container pack).
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920023309A 1991-11-26 1992-12-04 소염 또는 진통제 KR930009605A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB919126027A GB9126027D0 (en) 1991-12-06 1991-12-06 Medicaments
GB9126027.3 1991-12-06
GB929206083A GB9206083D0 (en) 1992-03-20 1992-03-20 Medicaments

Publications (1)

Publication Number Publication Date
KR930009605A true KR930009605A (ko) 1993-06-21

Family

ID=26299971

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920023309A KR930009605A (ko) 1991-11-26 1992-12-04 소염 또는 진통제

Country Status (26)

Country Link
US (1) US5466436A (ko)
EP (1) EP0550083B1 (ko)
JP (1) JPH05246853A (ko)
KR (1) KR930009605A (ko)
AP (1) AP324A (ko)
AT (1) AT401468B (ko)
AU (1) AU664574B2 (ko)
BE (1) BE1007268A3 (ko)
CA (1) CA2084568A1 (ko)
CH (1) CH685537A5 (ko)
CZ (1) CZ358092A3 (ko)
DE (1) DE69228738D1 (ko)
DK (1) DK0550083T3 (ko)
ES (1) ES2130152T3 (ko)
FR (1) FR2684554B1 (ko)
GB (1) GB2262036B (ko)
GR (1) GR3030426T3 (ko)
IE (1) IE922866A1 (ko)
IL (1) IL103978A (ko)
IT (1) IT1256697B (ko)
LU (1) LU88196A1 (ko)
MX (1) MX9207008A (ko)
MY (1) MY108146A (ko)
NO (1) NO303670B1 (ko)
NZ (1) NZ245365A (ko)
PH (1) PH31380A (ko)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501560D0 (en) 1995-01-26 1995-03-15 Nycomed Imaging As Contrast agents
HUP9900428A2 (hu) * 1995-01-26 1999-06-28 Nycomed Imaging A/S Bizmutvegyületek, ezeket tartalmazó diagnosztikai kontrasztanyag, ennek alkalmazása és ezt tartalmazó gyógyászati készítmény
EP0941101A1 (en) * 1996-11-22 1999-09-15 The Procter & Gamble Company Compositions for the treatment of gastrointestinal disorders containing bismuth, and nsaid and one or more antimicrobials
CN1238694A (zh) * 1996-11-22 1999-12-15 普罗克特和甘保尔公司 治疗肠胃病用的含铋和nsaid的组合物
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
JP2004520422A (ja) * 2001-03-08 2004-07-08 アストラゼネカ・アクチエボラーグ 新しい用途
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
WO2002098352A2 (en) 2001-06-01 2002-12-12 Pozen Inc. PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
CN101257800B (zh) * 2005-07-18 2012-07-18 好利用医疗公司 包含法莫替丁和布洛芬的药物
US20080020040A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Unit dose form for administration of ibuprofen
US20080021078A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
US8067451B2 (en) * 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
US8067033B2 (en) * 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
EP2063873A2 (en) * 2006-08-31 2009-06-03 Horizon Therapeutics, Inc. Nsaid dose unit formulations with h2-receptor antagonists and methods of use
CA2736547C (en) 2008-09-09 2016-11-01 Pozen Inc. Method for delivering a pharmaceutical composition to patient in need thereof
AU2010263304A1 (en) 2009-06-25 2012-02-02 Astrazeneca Ab Method for treating a patient at risk for developing an NSAID-associated ulcer
MX2014007935A (es) 2011-12-28 2014-11-14 Pozen Inc Composiciones y metodos mejorados para el suministro de omeprazol y de acido acetilsalicilico.
CN110893233A (zh) * 2019-12-19 2020-03-20 川北医学院附属医院 一种鸢尾素在制备抗炎药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464679A (en) * 1981-07-06 1984-08-07 Rca Corporation Method and apparatus for operating a microprocessor in synchronism with a video signal
GB2105193B (en) * 1981-09-04 1984-09-12 Glaxo Group Ltd Pharmaceutical compositions containing non-steroidal anti-inflammatory agents
SE8302689L (sv) * 1982-05-14 1983-11-15 Richter Gedeon Vegyeszet Farmaceutiska kompositioner innehallande flera aktiva bestandsdelar
US4757060A (en) * 1986-03-04 1988-07-12 Bristol-Myers Company Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 and H2, receptor blockers
GB8625325D0 (en) * 1986-10-22 1986-11-26 Glaxo Group Ltd Chemical compounds
ATE81011T1 (de) * 1987-03-09 1992-10-15 Procter & Gamble Zusammensetzungen und ihre verwendung zur behandlung von magen-darmstoerungen.
IL85472A (en) * 1987-03-09 1991-06-30 Procter & Gamble Pharmaceutical compositions for treating gastrointestinal disorders
CH679582A5 (ko) * 1988-07-18 1992-03-13 Glaxo Group Ltd
NZ235877A (en) * 1989-11-02 1992-09-25 Mcneil Ppc Inc Composition comprising acetaminophen or nsaid and an h 1 or h 2 receptor blocker and/or proton pump inhibitor for treating overindulgence
GB9019875D0 (en) * 1990-09-11 1990-10-24 Glaxo Group Ltd Pharmaceutical compositions
US5128140A (en) * 1991-01-14 1992-07-07 The Procter & Gamble Company Swallowable pharmaceutical compositions

Also Published As

Publication number Publication date
ITRM920869A0 (it) 1992-12-04
US5466436A (en) 1995-11-14
ES2130152T3 (es) 1999-07-01
PH31380A (en) 1998-10-29
FR2684554A1 (fr) 1993-06-11
GB2262036A (en) 1993-06-09
ITRM920869A1 (it) 1994-06-04
EP0550083A1 (en) 1993-07-07
IL103978A (en) 1998-06-15
CA2084568A1 (en) 1993-06-07
JPH05246853A (ja) 1993-09-24
FR2684554B1 (fr) 1995-09-08
NO303670B1 (no) 1998-08-17
LU88196A1 (fr) 1993-08-17
NZ245365A (en) 1997-06-24
DK0550083T3 (da) 1999-10-11
AU664574B2 (en) 1995-11-23
AP324A (en) 1994-03-07
NO924704L (no) 1993-06-07
GR3030426T3 (en) 1999-09-30
IE922866A1 (en) 1993-06-16
GB2262036B (en) 1996-01-03
NO924704D0 (no) 1992-12-04
IL103978A0 (en) 1993-05-13
EP0550083B1 (en) 1999-03-24
AP9200453A0 (en) 1993-01-31
MY108146A (en) 1996-08-30
DE69228738D1 (de) 1999-04-29
IT1256697B (it) 1995-12-12
GB9225174D0 (en) 1993-01-20
AU2986392A (en) 1993-06-10
CH685537A5 (fr) 1995-08-15
AT401468B (de) 1996-09-25
MX9207008A (es) 1993-06-01
BE1007268A3 (fr) 1995-05-09
ATA240692A (de) 1996-02-15
CZ358092A3 (en) 1993-10-13

Similar Documents

Publication Publication Date Title
KR930009605A (ko) 소염 또는 진통제
ES2106785T5 (es) Medicamentos, su preparacion y empleo como analgesicos y/o antiinflamatorios para seres humanos y animales.
ES2235152T3 (es) Un compuesto que comprende un material tramadol y un antiinflamatorio no esteroide.
CA1319887C (en) Non-steroidal anti-inflammatory compositions protected against gastro-intestinal injury with a combination of certain h _and h _receptor blockers
BR122012014331A8 (pt) Formulações farmacêuticas
AR028299A1 (es) Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
KR910009254A (ko) 과식 및/또는 과음후 증상을 치료하기 위한 약제학적 조성물 및 방법
KR920703046A (ko) 경구용 항응고제/혈소판 억제제 저용량 제형
JPS60208913A (ja) 高めた無痛覚を与える製薬製品
KR930007441A (ko) 의약품
RU2218180C2 (ru) Комбинация анальгетиков
BR0013719A (pt) Dosagem oral de liberaçâo controlada, apropriada para administração oral
KR970032872A (ko) 아세틸살리실산을 함유하는 피부 손상 처치용 약물
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
KR890014110A (ko) 의약제
JPH0314812B2 (ko)
KR890014109A (ko) 의약제
KR0175345B1 (ko) 장점막 장애 예방 및 치료제
Cailleteau Ketoprofen in dentistry: a pharmacologic review
KR870009716A (ko) 클로르페니라민 제형
US20060141027A1 (en) Sublingual administration of non-steroidal anti-inflammatory pharmacological substances
NZ193239A (en) Anti-inflammatory compositions containing 1-(4-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid and a 2-hydroxy-5-halophenylbenzoic acid derivative
Ranløv et al. Faecal blood loss during administration of acetylsalicylic acid, ketoprofen and two new ketoprofen sustained-release compounds
ATE250414T1 (de) Pharmazeutische zubereitungen enthaltend eine kombination aus isosorbid-nitrat und acetylsalicylsaeure
JP2586922B2 (ja) ある種のｈ▲下１▼およびｈ▲下２▼受容体遮断剤の組合せにより消化管損傷に対して保護された非ステロイド系抗炎症組成物

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application